« Previous article
SARS-CoV-2 PCR Test ...

14th June 2021  Product update: rapidvirology staff writer

Indonesia Receives COVID-19 Testing and Passport Platform

Achiko AG has announced that its digital passporting service mobile app, Teman Sehat (Health Buddy), has been successfully integrated with AptameX, its proprietary non-invasive, saliva-based COVID-19 diagnostic test for launch in Indonesia.

Teman Sehat works in combination with AptameX and provides an accurate, low-cost, state-of-the-art digital ecosystem that can schedule COVID-19 testing, receive payments, and obtain test results within a few minutes to help mitigate the spread of COVID-19.

The AptameX COVID-19 test results are analyzed to determine whether the presence of the virus has been detected. Users receive their result on the Teman Sehat app within 15 minutes in the form of a "Green" health pass if the test result is negative. Utilizing the health pass, entry into various locations can then be facilitated. If the result is positive, users are alerted of their positive test result and asked to take the necessary precautions.

Especially in regions severely affected by COVID-19, Teman Sehat provides an easy-to-use COVID-19 digital health passport service that can be used to secure specific locations such as malls or neighborhoods from further spread of the virus.

“It is evident that COVID-19 is going to be with us for quite some time,” stated Steven Goh, CEO of Achiko. “The combination of Teman Sehat and AptameX, particularly at its low price point and strong performance, has the potential to allow communities and workplaces to function almost normally whilst waiting for vaccination technologies to mature and to become available. Combining all these measures will enable us to beat COVID-19 globally,” added Goh.

The milestone with Teman Sehat follows preliminary results indicating a sensitivity of 77.59% when compared against RT-PCR results with a mean industry CT score of 28.3 (95% CI:75.94-79.24). The Company expects the results to improve as it moves to production and commercial availability later this year.

Test sites (e.g. hospitals, clinics, offices, airports etc.) will be able to operate Teman Sehat in conjunction with the saliva-based COVID-19 test kit, AptameX. The UV-VIS spectrophotometer transmits results wirelessly via Bluetooth with the entire testing process from booking through testing to diagnosis being managed through a PC or a mobile device in a one-stop-shop format. The open API of Teman Sehat also allows for third-party tests to be integrated.

“Teman Sehat’s growing market reach in Indonesia currently amounts to approximately 250,000 subscribers, and thanks to the low price of our tests (less than the price of a cup of coffee), we expect to be able to safeguard possibly 2% of Indonesia's 270 million population by later this year at 3-5 tests per person per month,” said Dr. Morris S. Berrie, President at Achiko.



Date Published: 14th June 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.

View full company details

Related news